<DOC>
	<DOCNO>NCT02781571</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability sofosbuvir /velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) participants chronic hepatitis C virus ( HCV ) receive liver transplant .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed Dose Combination Participants With Chronic Hepatitis C Virus Infection Who Have Received Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key History chronic HCV prior liver transplant HCV reoccurrence posttransplant HCV genotype 1 , 2 , 3 , 4 , 5 , 6 , indeterminate Individuals â‰¥ 3 month postliver transplant chronic HCV reoccurrence Male nonpregnant/ nonlactating female individual without cirrhosis compensate cirrhosis Metavir stage 3 4 fibrosis/cirrhosis correspond fibrosis Key History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol , Coinfection HIV hepatitis B virus Known hypersensitivity study medication , Use prohibit concomitant medication within window Day 1 visit . NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>